.svg)
Modified-release drug delivery systems are developed to control the rate and site of drug release to achieve optimal therapeutic outcomes. Some advantages of using modified-release drug products include improved therapeutic efficiency, reduced adverse effects, and increased patient compliance and convenience.
The use of modified release drug delivery systems also offers significant advantages to manufacturers. For example, dosage strength can be adjusted by varying excipients or pellet quantities while filling capsules. In addition, multiple Active Pharmaceutical Ingredients (APIs) can be combined within a single modified-release dosage form to create fixed-dose combinations.
Several factors are driving the demand for modified-release drug products. Manufacturers are increasingly developing improved formulations based on existing molecules. Although these products may generate lower revenues than new chemical entities (NCEs), they offer lower development costs, reduced regulatory risk, and faster time to market.
Over the past 15 years, many blockbuster drugs have lost patent protection and entered the generic market. This has created significant opportunities for pharmaceutical companies to develop differentiated products using modified-release dosage forms.
Modified-release formulations offer important therapeutic advantages, primarily through:
Modified-release oral dosage technologies are particularly valuable when:
Some key benefits include improved therapeutic efficiency, reduced adverse effects, and enhanced patient compliance. These systems also offer advantages to manufacturers, such as flexibility in dosage design and the ability to develop fixed-dose combinations.
Extended-release pellets are helpful for all drugs with a shorter-than-optimal half-life. They can maintain therapeutic blood level concentrations over prolonged periods with once-daily usage. Furthermore, adverse side effects resulting from transiently high concentrations can be greatly avoided.
Drugs generally need to be given at frequent intervals throughout the day to maintain better blood concentration levels within the desired therapeutic range. The potential reduction of daily dosages offered by extended-release products can improve patient compliance and also help in avoiding missed doses.
The enteric coating is generally used to protect the product until it has passed the gastric bladder and reached the gut. It serves to preserve acid-sensitive drugs from gastric acid and might reduce the likelihood of certain drugs irritating the stomach.
Modified-release technologies enable the development of fixed-dose combinations (FDCs), where two or more APIs are delivered in a single dosage form with optimised release profiles.
These formulations offer significant advantages:
FDCs are widely used in managing infectious diseases such as HIV, tuberculosis, and malaria, as well as chronic conditions requiring combination therapy.
Pellet-based modified release systems allow multiple APIs with different release profiles to coexist in a single capsule, improving treatment efficiency and convenience.
Modified-release drug products provide value across the entire healthcare ecosystem.
Patients requiring long-term treatment benefit significantly from reduced dosing frequency, improved convenience, and sustained therapeutic effects.
Conditions such as cardiovascular disease, pain management, neurological disorders, and metabolic diseases require consistent drug concentrations for effective treatment.
Modified-release dosage forms help maintain stable plasma levels, improving clinical outcomes.
Controlled drug release reduces peak plasma concentrations, lowering the risk of dose-related adverse effects.
Modified release technologies offer strategic advantages to manufacturers, including:
These capabilities enable pharmaceutical companies to develop innovative, patient-centric therapies while maximising commercial potential.
A lot of progress has been made in developing high-performance polymers in the past decade for modified release dosage forms, including advanced pharmaceutical intermediate (PFI)-based drug delivery systems such as modified release tablets, oral thin films, and more. But developing MR formulations with alcohol-resistant properties remains a challenge. When a modified-release drug product containing active pharmaceutical ingredients (APIs) and formulated using specialised pharmaceutical intermediates is consumed with alcohol, the release mechanism can be affected adversely, which could lead to dose dumping. In the case of some elements like opioids, dose dumping can result in serious adverse events.
In addition, the development of modified-release drug products requires highly specialized equipment, advanced drug delivery technologies, and regulatory knowledge in both API formulation and pharmaceutical intermediate manufacturing. Unfortunately, several pharmaceutical companies neither have a sufficient number of projects nor the in-house expertise in PFI development, modified release formulation, and pharmaceutical manufacturing processes to justify the investment in these capabilities.
This is precisely where a specialised partner makes a difference. ZIM Laboratories develops and manufactures pharmaceutical pellets across a wide range of release profiles including immediate, delayed, controlled, sustained, and targeted release offering formulation partners precise control over drug release behaviour.
Modified-release drug products provide a sophisticated approach to drug delivery by enabling controlled release rates and targeted site-specific delivery, helping achieve clinical objectives that are often difficult with conventional dosage forms. The integration of APIs with functional pharmaceutical intermediates (PFIs) further strengthens formulation performance by supporting precise release control, improved stability, and better therapeutic outcomes. These technologies allow manufacturers to optimise drug release profiles and reduce dosing frequency, while also demanding specialised equipment, technical expertise, and regulatory understanding to ensure successful development and scalable commercial manufacturing.
ZIM Labs is an innovative drug delivery solution provider focusing on improving patient convenience and adherence to drug intake. We offer a range of technology-based drug delivery solutions and non-infringing proprietary manufacturing processes for the production and supply of innovative and differentiated generic pharmaceutical products to our customers globally. At ZIM Labs, we provide our customers a comprehensive range of value-added solid dosage differentiated generic products in semi-finished and finished categories/formulations. These include granules, pellets (immediate, sustained, modified, extended-release), taste-masked powders, suspensions, tablets, capsules, and recently developed Oral Thin Films (OTF).
